Evidence map›Paper›PMID 42365017›Full record

ArticleCell death discovery2026

NRP1 promotes hepatic fibrosis by regulating Src/Rab7-mediated lysosomal degradation of TβRI.

Zhe Jia, Xiaodong Song, Jie Bai

Abstract read
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhe JiaDepartment of General Surgery, Beijing Friendship Hospital, Capital Medical University & State Key Lab of Digestive Health & National Clinical Research Center for Digestive Diseases, Beijing, China.
Xiaodong SongDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jie BaiDepartment of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. docbai@yeah.net.

Funding

Chongqing Postdoctoral Science Foundation No. CSTB2023NSCQ-BHX0181National Natural Science Foundation of China (National Science Foundation of China) No. 82300704
6 · The paper itself

Abstract

BACKGROUND AND

aimsActivation of hepatic stellate cells (HSCs) and subsequent dysregulation of the TGF-β1 signaling pathway are central to the progression of hepatic fibrosis. Neuropilin-1 (NRP1) has been identified as a co-receptor involved in multiple signaling pathways, yet its role in modulating TGF-β receptor stability in HSCs remains to be fully elucidated. This study investigated the regulatory role of the NRP1/Src/Rab7 axis in TβRI lysosomal degradation during HSC activation.

methodsHepatic fibrosis was induced in male C57BL/6 mice via intraperitoneal CCl

resultsNrp1 silencing in primary HSCs reduced TβRI protein levels and attenuated p-Smad2/3 signaling without affecting mRNA levels. Consistently, NRP1 deficiency accelerated lysosomal degradation of TβRI, accompanied by increased TβRI-LAMP1 colocalization and enhanced trafficking of TβRI into Rab7-positive late endosomes. Mechanistically, NRP1 loss diminished Src kinase activity and consequently reduced Src-dependent tyrosine phosphorylation of Rab7, leading to elevated Rab7-GTP levels and enhanced late endosomal sorting of TβRI. Rab7 knockdown or Src reactivation partially rescued TβRI stability and restored downstream signaling. In vivo, HSC-specific Nrp1 knockdown attenuated CCl

conclusionsThese data suggest that the NRP1/Src/Rab7 axis contributes to TβRI stability by modulating its lysosomal degradation pathway. Targeting this axis may provide a potential approach for intervening in the progression of hepatic fibrosis.

Identifiers

PMID42365017
PMCPMC13572504

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.